Probiotics for Women: Strains and What Women’s Labels Contain

By Erin Rose · Published September 16, 2026 · Reviewed against primary sources · Methodology · About Us

Informational summary of published trials and guidelines, not medical advice. Vaginal or urinary symptoms need a clinician’s diagnosis; a probiotic is not a treatment. If you are pregnant, immunocompromised or critically ill, ask your clinician before taking any live organism.

Know your strain already? See the probiotic comparison, with strain, research and cost per day →

Published trials by topic, with the dose the trials used

Probiotic evidence is strain-specific and disease-specific: a systematic review of 228 trials found that efficacy tracked the specific strain and the specific condition, and that strains of the same species did not share results (McFarland 2018, PMID 29868585). So the table starts from the trial topic. Doses are the ones the cited trial used; the strain code after the species name is the part of a label that maps to a trial.

Route matters as much as strain. Every intravaginal result above is an investigational product that is not on sale; supplements are oral, and only GR-1 and RC-14 have shown that the oral route reaches the vaginal tract.

Vaginal health: two strains have the trials, one organism dominates the healthy state

A healthy vagina is usually dominated by a single Lactobacillus species. When 396 asymptomatic women were sequenced, their vaginal communities fell into five groups: four dominated by L. crispatus, L. iners, L. gasseri or L. jensenii, and a fifth with fewer lactobacilli and more anaerobes, the pattern associated with bacterial vaginosis (Ravel 2011, PMID 20534435). None of those four is the L. acidophilus or L. plantarum that fills most women’s-probiotic labels.

The oral evidence belongs to two strains. In a randomized trial, 64 healthy women took capsules of L. rhamnosus GR-1 and L. reuteri RC-14 (then called L. fermentum RC-14) or placebo daily for 60 days: the flora shifted from an asymptomatic BV pattern to a normal lactobacilli pattern in 37% of the probiotic group against 13% on placebo, with less yeast and fewer coliforms on culture and no adverse effects (Reid 2003, PMID 12628548). The dose-finding study that preceded it is the one to remember when reading labels: more than 10⁸ viable organisms a day was the dose required, and L. rhamnosus GG, the most-studied probiotic strain in the world and the one in Culturelle, failed to have any effect on vaginal flora (Reid 2001, PMID 11750220).

For diagnosed bacterial vaginosis, the strains have been studied only as an add-on to the antibiotic, not a substitute. One trial in 125 premenopausal women with BV treated with oral metronidazole tested adding GR-1 and RC-14 or placebo (Anukam 2006, PMID 16697231). The Cochrane review that weighed this and three other trials called the evidence insufficient for or against recommending probiotics for BV (Senok 2009, PMID 19821358). That is the honest reading: one trial, no confirmation at scale.

The best recurrence result in the research uses the dominant organism directly. Lactin-V, an intravaginal L. crispatus CTV-05 product, was tested for 11 weeks after metronidazole gel in 228 women and reported BV recurrence by week 12 of 30% against 45% on placebo (Cohen 2020, PMID 32402161). It is an investigational product, not a capsule you can buy, and the organism it uses is the one almost no label carries. For yeast infections the picture is weaker. The Cochrane review of 10 trials in 1,656 non-pregnant women of probiotics added to antifungals rated the evidence low or very low quality and found no difference in long-term cure (Xie 2017, PMID 29168557). The vaginal-health product page covers the GR-1/RC-14 products themselves.

Recurrent UTI: what the probiotic trials found

The Cochrane review of probiotics for preventing urinary tract infection included nine trials and 735 people and found no significant reduction in recurrent symptomatic UTI against placebo (six trials, 352 participants, RR 0.82, 95% CI 0.60 to 1.12), with a high risk of bias throughout (Schwenger 2015, PMID 26695595). A phase 2 trial gave 100 premenopausal women with recurrent UTI an intravaginal L. crispatus suppository or placebo after antibiotic treatment: recurrence was 15% against 27%, a relative risk of 0.5 whose confidence interval crossed 1, and the benefit tracked with how well the strain colonized (Stapleton 2011, PMID 21498386). And 252 postmenopausal women with recurrent UTI were randomized to a year of daily trimethoprim-sulfamethoxazole or oral GR-1/RC-14 at 10⁹ CFU twice daily: the probiotic group averaged 3.3 UTIs a year against 2.9, which missed the noninferiority margin, but their E. coli did not become resistant, while in the antibiotic group resistance climbed from roughly 20–40% to 80–95% within a month (Beerepoot 2012, PMID 22782199).

So an oral probiotic is not an established UTI preventive, nor a substitute for prophylaxis a clinician has prescribed. Cranberry, which some women’s labels add, has its own separate research (Williams 2023, PMID 37947276); a probiotic capsule with a token amount of cranberry is not that research. Talk to a clinician about recurrent UTIs.

IBS and the gut: one strain has a trial in women, the guidelines still say no to the class

The largest single-strain IBS trial was run in women. 362 primary-care patients took placebo or encapsulated Bifidobacterium infantis 35624 at 10⁶, 10⁸ or 10¹⁰ CFU a day for four weeks; the 10⁸ dose beat placebo on abdominal pain, bloating and gas, the 10⁶ dose did nothing, and the 10¹⁰ dose was no better (Whorwell 2006, PMID 16863564). That is the clearest demonstration that more CFU is not more effect.

Step back to the whole evidence base and the picture blurs. A meta-analysis of 53 trials in 5,545 IBS patients found that particular strains appeared to help global symptoms and pain, but which ones remained, in the authors’ words, for the most part unclear (Ford 2018, PMID 30294792). The American College of Gastroenterology guideline that followed suggests against probiotics for global IBS symptoms (Lacy 2021, PMID 33315591), and the American Gastroenterological Association guideline recommends probiotics for IBS only within a clinical trial, reserving its positive suggestions for narrow settings such as preventing C. difficile infection during antibiotics (Su 2020, PMID 32531291). See the probiotics overview for the strain research.

Nothing in the IBS evidence is specific to women beyond the trial population. A gut probiotic does not need to say “women’s” on the box.

Pregnancy and antibiotics: what the reviews found

Pregnancy first. A meta-analysis of 11 randomized trials of Lactobacillus and Bifidobacterium in 1,505 pregnant women found no effect on cesarean section, birth weight or gestational age and no malformations; it found no pregnancy trials of Saccharomyces at all, so the safety of S. boulardii in pregnancy is unknown (Dugoua 2009, PMID 19646321). A 2021 review reached the same conclusion for pregnancy and lactation, with one trial reporting more vaginal discharge and changes in stool consistency on L. rhamnosus plus L. reuteri and nothing serious (Sheyholislami 2021, PMID 34371892). Across 622 studies in the wider safety literature, randomized trials showed no increase in adverse events with short-term use; the case reports of fungemia and bacteremia cluster in people whose health was already compromised (Hempel 2011, PMID 23126627).

Antibiotics are the use with the most probiotic research. In a meta-analysis of 63 randomized trials with 11,811 participants, antibiotic-associated diarrhea was 42% lower with probiotics (RR 0.58, 95% CI 0.50 to 0.68), with a number needed to treat of 13 (Hempel 2012, PMID 22570464). The pediatric Cochrane review of 33 trials put the incidence at 8% with a probiotic against 19% without (Guo 2019, PMID 31039287). L. rhamnosus GG and S. boulardii are the best-tested. Ask your clinician or pharmacist about timing with any medication. The probiotics overview covers the strain research.

We read 896 probiotic labels: what a “women’s probiotic” actually contains

Original research Every on-market probiotic label filed with the NIH Dietary Supplement Label Database that we could retrieve (900 read, 896 analyzed), split into 77 women-marketed labels (the product name says women, her, feminine or vaginal) and 819 general labels, with the organisms named in the Supplement Facts rows tallied by label. This census counts strains named, not dose: DSLD does not carry CFU as a machine-readable quantity, so no figure here says how much of any strain a capsule holds.

14.3% of women’s labels name L. rhamnosus GR-1 or L. reuteri RC-14, the two strains with the vaginal trials; about one label in 7. 2.6% name L. crispatus, the organism that dominates the healthy vaginal state and the one in the BV-recurrence and UTI trials, against 0.5% of general labels. And 93.5% of women’s labels put their strains inside a proprietary-blend row: a total for the blend, nothing for any strain in it. The typical general label names 5 species. Only 8.8% of general labels carry a CFU figure the database can read as a quantity.

Putting the two parts of this page together: The trials that justify a probiotic for vaginal health used two named strains at a stated dose; the product built for that shopper names them one time in 7, and in 93.5% of cases would not state the dose even if it did. What fills the label instead is a longer list of species with gut trials or none, plus cranberry or D-mannose for the UTI reader. We only print figures that held up when we re-checked them. What survives is enough: the women’s shelf is a general probiotic with a different name.

Method: 900 labels retrieved from the NIH Dietary Supplement Label Database (DSLD) v9 on 2026-09-16; 896 were analyzable, of which 77 carry women, her, feminine or vaginal in the product name and 819 do not. Organisms were read from the Supplement Facts rows, including rows inside a proprietary blend; a label counts as naming a strain if the strain designation appears anywhere in its rows. CFU was counted only when DSLD records it as a structured quantity, which is rare, so this census reports strains named and makes no claim about dose. Percentages are against the labels in each group. The figures are published as open data (CC BY 4.0). What it cannot tell you: how many CFU of any strain a capsule holds, whether the strain named is viable at expiry, which products sell most, or anything about products not filed with the NIH.

The product links below go to Amazon and we may earn a commission if you buy. It never changes which product we pick or what we say about it. How we choose.

Frequently asked questions

Related guides

• Probiotics for vaginal health (the GR-1/RC-14 products and their availability)
• Probiotic comparison (every product we track, with strain and cost per day)
• Probiotics overview (strains and published research)
• Probiotic dosage guide (CFU ranges used in studies and the label catch)
• Iron for women
• Vitamin D for women

Sources